Objective Microcystin-leucine-arginine(MC-LR)exposure induces lipid metabolism disorders in the liver.Secreted frizzled-related protein 5(SFRP5)is a natural antagonist of winglesstype MMTV integration site family,memb...Objective Microcystin-leucine-arginine(MC-LR)exposure induces lipid metabolism disorders in the liver.Secreted frizzled-related protein 5(SFRP5)is a natural antagonist of winglesstype MMTV integration site family,member 5A(Wnt5a)and an anti-inflammatory adipocytokine.In this study,we aimed to investigate whether MC-LR can induce lipid metabolism disorders in hepatocytes and whether SFRP5,which has anti-inflammatory effects,can alleviate the effects of hepatic lipid metabolism by inhibiting the Wnt5a/Jun N-terminal kinase(JNK)pathway.Methods We exposed mice to MC-LR in vivo to induce liver lipid metabolism disorders.Subsequently,mouse hepatocytes that overexpressed SFRP5 or did not express SFRP5 were exposed to MC-LR,and the effects of SFRP5 overexpression on inflammation and Wnt5a/JNK activation by MC-LR were observed.Results MC-LR exposure induced liver lipid metabolism disorders in mice and significantly decreased SFRP5 mRNA and protein levels in a concentration-dependent manner.SFRP5 overexpression in AML12cells suppressed MC-LR-induced inflammation.Overexpression of SFRP5 also inhibited Wnt5a and phosphorylation of JNK.Conclusion MC-LR can induce lipid metabolism disorders in mice,and SFRP5 can attenuate lipid metabolism disorders in the mouse liver by inhibiting Wnt5a/JNK signaling.展开更多
Objective Obstructive sleep apnea (OSA) is closely related to obesity, insulin resistance and inflammation. Secreted frizzled-related protein 5 (SFRP5) is a recently discovered adipokine. It is involved in insulin res...Objective Obstructive sleep apnea (OSA) is closely related to obesity, insulin resistance and inflammation. Secreted frizzled-related protein 5 (SFRP5) is a recently discovered adipokine. It is involved in insulin resistance and inflammation in obesity. This study aimed at evaluating the association between SFRP5and sleeping characteristics as well as biochemical parameters of OSA patients.Methods This was a prospective case control study. Nondiabetic OSA patients and controls were consecutively recruited and divided into three groups: OSA group, apnea–hypopnea Index (AHI)≥5/h; healthy controls with normal body mass index (BMI); obese controls without OSA, and BMI > 24.0 kg/m2. All participants underwent polysomnography (PSG). Plasma SFRP5 was examined using enzyme-linked immunosorbent assay (ELISA). Blood biochemical examinations, including fasting blood glucose (FBG), lipid profile, hypersensitive Creactive protein (hsCRP), were performed early in the morning after PSG. Patients with severe OSA were treated with nasal continuous positive airway pressure (nCPAP), and plasma SFRP5 was repeatedly measured for comparison.Results Sixty-eight subjects were enrolled in the study, including 38 patients of OSA, whose medium AHI was 58.70 /h (36.63, 71.15), 20 obese controls, and 10 healthy controls. The plasma SFRP5 level of OSA patients was not significantly different from that of healthy controls or obese controls. In OSA patients, SFRP5 level correlated positively with triglyceride level (r=0.447, P=0.005) and negatively with LDL-cholesterol level and HDLcholesterol level (r=?0.472 and P=0.003; r=?0.478 and P=0.002; respectively). SFRP5 level was not found correlating with FBG, AHI, or any of nocturnal hypoxia parameters. After overnight nCPAP treatment, plasma SFRP5 levels of OSA patients did not change significantly (t=1.557, P = 0.148) compared to that of pretreatment.Conclusions In nondiabetic OSA patients, plasma SFRP5 is associated with the lipid profile. However,no correlation was observed between SFRP5 and FBG or sleep parameters. The SFRP5 level of OSA patients did not differ from that of non-OSA individuals in our study.展开更多
Objective:To investigate the correlation between serum secretory frizzled-related protein 5(SFRP-5)expression levels and insulin resistance and glucolipid metabolism in patients with gestational diabetes mellitus(GDM)...Objective:To investigate the correlation between serum secretory frizzled-related protein 5(SFRP-5)expression levels and insulin resistance and glucolipid metabolism in patients with gestational diabetes mellitus(GDM).Methods:Baseline data were collected from 58 patients with GDM and 51 healthy controls who were admitted Affiliated Hospital of Hebei University from May 2020 to June 2022.sSTRA5 concentrations in peripheral blood of pregnant women were measured,and SFRP-5 levels in patients with different GDM types and normal controls were analyzed by logistic regression models.Results:The levels of triglyceride(TG),total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),fasting blood glucose(FBG),fasting insulin(FINS),hemoglobin A1c(HbA1c),and homeostasis model assessment-estimated insulin resistance(HOMA-IR)were higher in the observation group than in the control group,with statistically significant differences(P<0.05),while the expression levels of high-density lipoprotein cholesterol(HDL-C)and serum SFRP-5 were lower than in the control group,with statistically significant differences(P<0.05);serum SFRP-5,TG,TC,FBG,and HOMA-IR were all risk factors for GDM(P<0.05).Conclusion:Elevated serum sSTRA5 may be involved in the regulation of insulin resistance in the body and the regulation of blood glucose in the body by affecting lipid metabolism and inflammatory response.展开更多
目的观察不同减重方式对2型糖尿病肥胖患者内脏脂肪含量、血糖控制及分泌型卷曲相关蛋白5(secretory curl related protein 5,SFRP5)、脂联素(adiponectin,APN)、瘦素(leptin,LP)的调节作用,以期寻找一种更适合于糖尿病合并肥胖人群的...目的观察不同减重方式对2型糖尿病肥胖患者内脏脂肪含量、血糖控制及分泌型卷曲相关蛋白5(secretory curl related protein 5,SFRP5)、脂联素(adiponectin,APN)、瘦素(leptin,LP)的调节作用,以期寻找一种更适合于糖尿病合并肥胖人群的减重、降糖模式。方法选取2018-06/2020-12月作者医院2型糖尿病肥胖患者195例,以随机数字表法分为试验A组、试验B组、试验C组、试验D组、对照组,每组各39例。试验A组给予限制热量平衡饮食,试验B组给予正常热量饮食联合口服二甲双胍、试验C组给予正常热量饮食联合口服奥利司他、试验D组给予正常热量饮食联合利拉鲁肽,对照组给予正常热量饮食,均治疗3个月。比较5组治疗前、治疗3个月后体质量、体质量指数(body mass index,BMI)、腰围、内脏脂肪含量、糖化血红蛋白(haemoglobin A1c,HbA1c)、空腹血糖(fasting blood glucose,FPG)、餐后2 h血糖(postprandial 2-hour blood glucose,2hPG)、高密度脂蛋白胆固醇(high-density lipoprotein cholesterol,HDL-C)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)、总胆固醇(total cholesterol,TC)、甘油三酯(triglycerides,TG)、稳态模型胰岛素抵抗指数(homeostatic model assessment for insulin resistance,HOMA-IR)、稳态模型胰岛β细胞功能指数(homeostatic model assessment ofβ-cell function,HOMA-β)、SFRP5、APN、LP水平。结果治疗3个月后,(1)患者体质量、BMI、腰围、内脏脂肪含量组间比较,试验C组<试验D组<试验B组<试验A组<对照组(P<0.05);(2)HbA1c、FPG、2hPG水平组间比较,试验B组和试验D组<试验C组<试验A组<对照组(P<0.05);(3)LDL-C、TC、TG水平组间比较,试验C组<试验D组<试验B组<试验A组<对照组(P<0.05),HDL-C水平的组间比较,试验C组>试验D组>试验B组>试验A组>对照组(P<0.05);(4)HOMA-IR、HOMA-β水平组间比较,试验B组和试验D组<试验C组<试验A组<对照组(P<0.05);(5)血清SFRP5水平组间比较,试验D组>试验C组>试验B组>试验A组>对照组(P<0.05),APN水平组间比较,试验C组>试验D组>试验B组>试验A组>对照组(P<0.05),LP水平组间比较,试验C组<试验D组<试验B组<试验A组<对照组(P<0.05)。结论2型糖尿病肥胖患者采用二甲双胍、利拉鲁肽治疗降糖、调节胰岛素敏感性作用显著,采用奥利司他治疗减重、降脂效果显著,还可调节SFRP5、APN、LP表达水平,减轻LP抵抗状态,加速脂肪分解及糖代谢。展开更多
基金supported by the Natural Science Research Project of colleges and Universities in Anhui Province[2022AH052336]High Level Talent Research Initiation Fund Of Anhui Medical College[2023RC004]。
文摘Objective Microcystin-leucine-arginine(MC-LR)exposure induces lipid metabolism disorders in the liver.Secreted frizzled-related protein 5(SFRP5)is a natural antagonist of winglesstype MMTV integration site family,member 5A(Wnt5a)and an anti-inflammatory adipocytokine.In this study,we aimed to investigate whether MC-LR can induce lipid metabolism disorders in hepatocytes and whether SFRP5,which has anti-inflammatory effects,can alleviate the effects of hepatic lipid metabolism by inhibiting the Wnt5a/Jun N-terminal kinase(JNK)pathway.Methods We exposed mice to MC-LR in vivo to induce liver lipid metabolism disorders.Subsequently,mouse hepatocytes that overexpressed SFRP5 or did not express SFRP5 were exposed to MC-LR,and the effects of SFRP5 overexpression on inflammation and Wnt5a/JNK activation by MC-LR were observed.Results MC-LR exposure induced liver lipid metabolism disorders in mice and significantly decreased SFRP5 mRNA and protein levels in a concentration-dependent manner.SFRP5 overexpression in AML12cells suppressed MC-LR-induced inflammation.Overexpression of SFRP5 also inhibited Wnt5a and phosphorylation of JNK.Conclusion MC-LR can induce lipid metabolism disorders in mice,and SFRP5 can attenuate lipid metabolism disorders in the mouse liver by inhibiting Wnt5a/JNK signaling.
文摘Objective Obstructive sleep apnea (OSA) is closely related to obesity, insulin resistance and inflammation. Secreted frizzled-related protein 5 (SFRP5) is a recently discovered adipokine. It is involved in insulin resistance and inflammation in obesity. This study aimed at evaluating the association between SFRP5and sleeping characteristics as well as biochemical parameters of OSA patients.Methods This was a prospective case control study. Nondiabetic OSA patients and controls were consecutively recruited and divided into three groups: OSA group, apnea–hypopnea Index (AHI)≥5/h; healthy controls with normal body mass index (BMI); obese controls without OSA, and BMI > 24.0 kg/m2. All participants underwent polysomnography (PSG). Plasma SFRP5 was examined using enzyme-linked immunosorbent assay (ELISA). Blood biochemical examinations, including fasting blood glucose (FBG), lipid profile, hypersensitive Creactive protein (hsCRP), were performed early in the morning after PSG. Patients with severe OSA were treated with nasal continuous positive airway pressure (nCPAP), and plasma SFRP5 was repeatedly measured for comparison.Results Sixty-eight subjects were enrolled in the study, including 38 patients of OSA, whose medium AHI was 58.70 /h (36.63, 71.15), 20 obese controls, and 10 healthy controls. The plasma SFRP5 level of OSA patients was not significantly different from that of healthy controls or obese controls. In OSA patients, SFRP5 level correlated positively with triglyceride level (r=0.447, P=0.005) and negatively with LDL-cholesterol level and HDLcholesterol level (r=?0.472 and P=0.003; r=?0.478 and P=0.002; respectively). SFRP5 level was not found correlating with FBG, AHI, or any of nocturnal hypoxia parameters. After overnight nCPAP treatment, plasma SFRP5 levels of OSA patients did not change significantly (t=1.557, P = 0.148) compared to that of pretreatment.Conclusions In nondiabetic OSA patients, plasma SFRP5 is associated with the lipid profile. However,no correlation was observed between SFRP5 and FBG or sleep parameters. The SFRP5 level of OSA patients did not differ from that of non-OSA individuals in our study.
基金Youth Science and Technology Fund of Affiliated Hospital of Hebei University(Project number:2017Q024)Baoding City Science and Technology Plan Projects(Project number:2041ZF295)Hebei University Medical Subject Cultivation Project(Project number:2022B03)。
文摘Objective:To investigate the correlation between serum secretory frizzled-related protein 5(SFRP-5)expression levels and insulin resistance and glucolipid metabolism in patients with gestational diabetes mellitus(GDM).Methods:Baseline data were collected from 58 patients with GDM and 51 healthy controls who were admitted Affiliated Hospital of Hebei University from May 2020 to June 2022.sSTRA5 concentrations in peripheral blood of pregnant women were measured,and SFRP-5 levels in patients with different GDM types and normal controls were analyzed by logistic regression models.Results:The levels of triglyceride(TG),total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),fasting blood glucose(FBG),fasting insulin(FINS),hemoglobin A1c(HbA1c),and homeostasis model assessment-estimated insulin resistance(HOMA-IR)were higher in the observation group than in the control group,with statistically significant differences(P<0.05),while the expression levels of high-density lipoprotein cholesterol(HDL-C)and serum SFRP-5 were lower than in the control group,with statistically significant differences(P<0.05);serum SFRP-5,TG,TC,FBG,and HOMA-IR were all risk factors for GDM(P<0.05).Conclusion:Elevated serum sSTRA5 may be involved in the regulation of insulin resistance in the body and the regulation of blood glucose in the body by affecting lipid metabolism and inflammatory response.
文摘目的观察不同减重方式对2型糖尿病肥胖患者内脏脂肪含量、血糖控制及分泌型卷曲相关蛋白5(secretory curl related protein 5,SFRP5)、脂联素(adiponectin,APN)、瘦素(leptin,LP)的调节作用,以期寻找一种更适合于糖尿病合并肥胖人群的减重、降糖模式。方法选取2018-06/2020-12月作者医院2型糖尿病肥胖患者195例,以随机数字表法分为试验A组、试验B组、试验C组、试验D组、对照组,每组各39例。试验A组给予限制热量平衡饮食,试验B组给予正常热量饮食联合口服二甲双胍、试验C组给予正常热量饮食联合口服奥利司他、试验D组给予正常热量饮食联合利拉鲁肽,对照组给予正常热量饮食,均治疗3个月。比较5组治疗前、治疗3个月后体质量、体质量指数(body mass index,BMI)、腰围、内脏脂肪含量、糖化血红蛋白(haemoglobin A1c,HbA1c)、空腹血糖(fasting blood glucose,FPG)、餐后2 h血糖(postprandial 2-hour blood glucose,2hPG)、高密度脂蛋白胆固醇(high-density lipoprotein cholesterol,HDL-C)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)、总胆固醇(total cholesterol,TC)、甘油三酯(triglycerides,TG)、稳态模型胰岛素抵抗指数(homeostatic model assessment for insulin resistance,HOMA-IR)、稳态模型胰岛β细胞功能指数(homeostatic model assessment ofβ-cell function,HOMA-β)、SFRP5、APN、LP水平。结果治疗3个月后,(1)患者体质量、BMI、腰围、内脏脂肪含量组间比较,试验C组<试验D组<试验B组<试验A组<对照组(P<0.05);(2)HbA1c、FPG、2hPG水平组间比较,试验B组和试验D组<试验C组<试验A组<对照组(P<0.05);(3)LDL-C、TC、TG水平组间比较,试验C组<试验D组<试验B组<试验A组<对照组(P<0.05),HDL-C水平的组间比较,试验C组>试验D组>试验B组>试验A组>对照组(P<0.05);(4)HOMA-IR、HOMA-β水平组间比较,试验B组和试验D组<试验C组<试验A组<对照组(P<0.05);(5)血清SFRP5水平组间比较,试验D组>试验C组>试验B组>试验A组>对照组(P<0.05),APN水平组间比较,试验C组>试验D组>试验B组>试验A组>对照组(P<0.05),LP水平组间比较,试验C组<试验D组<试验B组<试验A组<对照组(P<0.05)。结论2型糖尿病肥胖患者采用二甲双胍、利拉鲁肽治疗降糖、调节胰岛素敏感性作用显著,采用奥利司他治疗减重、降脂效果显著,还可调节SFRP5、APN、LP表达水平,减轻LP抵抗状态,加速脂肪分解及糖代谢。
